Comparative efficacy of escitalopram in the treatment of major depressive disorder by Ali, Mazen K & Lam, Raymond W
© 2011 Ali and Lam, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2011:7 39–49
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
39
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/NDT.S12531
Comparative efficacy of escitalopram  
in the treatment of major depressive disorder
Mazen K Ali
Raymond w Lam
Department of Psychiatry,  
University of British Columbia,  
and Mood Disorders Centre, 
University of British Columbia 
Hospital, vancouver, Canada
Correspondence: Raymond w Lam 
Department of Psychiatry, University  
of British Columbia, 2255 wesbrook Mall, 
vancouver, BC, v6T 2A1, Canada 
Tel +1 604 822 7325 
Fax +1 604 822 7922 
email r.lam@ubc.ca
Background: Escitalopram is an allosteric selective serotonin reuptake inhibitor (SSRI) with 
some indication of superior efficacy in the treatment of major depressive disorder. In this 
  systematic review, we critically evaluate the evidence for comparative efficacy and tolerability 
of escitalopram, focusing on pooled and meta-analysis studies.
Methods: A literature search was conducted for escitalopram studies that quantitatively 
  synthesized data from comparative randomized controlled trials in MDD. Studies were excluded 
if they did not focus on efficacy, involved primarily subgroups of patients, or synthesized data 
included in subsequent studies. Outcomes extracted from the included studies were weighted 
mean difference or standard mean difference, response and remission rates, and withdrawal 
rate owing to adverse events.
Results: The search initially identified 24 eligible studies, of which 12 (six pooled analysis and 
six meta-analysis studies) met the criteria for review. The pooled and meta-analysis studies with 
citalopram showed significant but modest differences in favor of escitalopram, with weighted 
mean differences ranging from 1.13 to 1.73 points on the Montgomery Asberg Depression   Rating 
Scale, response rate differences of 7.0%–8.3%, and remission rate differences of 5.1%–17.6%. 
Pooled analysis studies showed efficacy differences compared with duloxetine and with serotonin 
noradrenaline reuptake inhibitors combined, but meta-analysis studies did not. The effect sizes 
of the efficacy differences increased in the severely depressed patient subgroups.
Conclusion: Based on pooled and meta-analysis studies, escitalopram demonstrates 
  superior efficacy compared with citalopram and with SSRIs combined. Escitalopram shows 
similar   efficacy to serotonin noradrenaline reuptake inhibitors but the number of trials in these 
  comparisons is limited. Efficacy differences are modest but clinically relevant, especially in 
more severely depressed patients.
Keywords: escitalopram, depressive disorders, meta-analysis, pooled analysis, efficacy, 
antidepressants
Introduction
Major depressive disorder (MDD) is a common and serious psychiatric condition with 
significant public health implications.1 The World Health Organization estimates that, by 
2030, MDD will be second only to ischemic heart disease as an overall cause of disability 
and disease burden.2 The economic costs of depression and its treatment are estimated 
at C$6 billion in Canada,3 US$83 billion in the US,4 and €118 billion in Europe.5
There are many evidence-based psychotherapy and pharmacotherapy treatments 
for MDD. Antidepressant medications remain a mainstay of treatment for MDD, 
especially for those with moderate to severe depression. Newer antidepressants, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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including   selective serotonin reuptake inhibitors (SSRIs), 
serotonin noradrenaline reuptake inhibitors (SNRIs), and 
novel mechanism agents offer fewer side effects and are 
safer in overdose compared with tricyclic antidepressants 
and monoamine oxidase inhibitors. Hence, most clinical 
guidelines consider the newer generation antidepressants to 
be first-line medications for MDD.6–8
Escitalopram, the S-enantiomer of racemic citalopram, 
is an SSRI that has an additional modulatory effect at an 
allosteric binding site on the serotonin transporter protein.9 
Escitalopram has been demonstrated in many placebo-
controlled, randomized, controlled trials to be an efficacious 
antidepressant for MDD.10,11 Moreover, some randomized 
controlled trials have shown evidence for the superior efficacy 
and tolerability of escitalopram compared with other SSRIs 
and other agents.12,13
Unfortunately, the evaluation of comparative efficacy of 
antidepressants is complex. Placebo-controlled, randomized, 
controlled trials remain the gold standard for   demonstrating 
the efficacy of treatments. However, most randomized 
controlled trials in MDD are designed to detect differences 
between an active antidepressant and placebo, and hence are 
not adequately powered to detect smaller, but still clinically 
relevant, differences between two active antidepressants.
Because of the limitations of randomized controlled   trials, 
meta-analysis to investigate the comparative effectiveness of 
  antidepressants is being increasingly used.14 Meta-analysis 
is a statistical technique to synthesize results from many 
randomized controlled trials. It can be a powerful method 
to increase power to detect differences between agents 
even when individual randomized controlled trials can-
not. There are two main types of meta-analysis, ie, those 
using pooled individual patient data (usually called pooled 
analysis studies) and those using summary data from 
  individual trials (more typically known as meta-analyses).15 
Pooled analysis studies have the advantages of considerable 
power and the ability to examine subgroups, because all 
individual patient data are available for analysis. However, 
randomized controlled trials can only be pooled if they 
have very similar study designs (eg, use the same outcome 
measure) and if investigators agree to release of individual 
patient data. The latter is very difficult to arrange, hence many 
pooled analysis studies report on trials from a single sponsor. 
In contrast, standard meta-analyses can synthesize data from 
very different types of randomized controlled trials, because 
a standardized effect size can be calculated for any outcome 
measure and only summary data from a trial are necessary.
Regardless of the type of meta-analysis, the details of 
meta-analysis methodology are as important for   interpretation 
of results as they are for randomized controlled trials. 
  Selection criteria for inclusion of studies is perhaps the most 
important aspect of meta-analysis. Results may differ widely 
depending on these criteria, including whether published or 
unpublished trials are included.15 Other important factors to 
consider include definitions of primary and secondary out-
comes, duration of trials, dose comparability, and assessment 
of heterogeneity and publication bias.14
The objective of this systematic review is to examine criti-
cally the evidence for the comparative efficacy and   tolerability 
of escitalopram, focusing on studies using pooled analysis 
and meta-analysis to synthesize randomized   controlled trial 
data.
Methods
A literature search was performed using PubMed with 
keywords  including  “escitalopram”,  “depression”, 
  “meta-analysis”, “pooled analysis”, and “systematic 
review”. We also scanned reference lists of review papers 
on   escitalopram. Studies were included if they conducted 
analyses that synthesized data on randomized controlled 
trials using pooled analysis and meta-analysis. Studies were 
excluded if they did not primarily examine efficacy or if they 
only examined patient subgroups.
All of the randomized controlled trials represented within 
these studies used the Montgomery-Asberg Depression 
Rating Scale (MADRS) or the Hamilton Depression Rating 
Scale (Ham-D) as primary outcomes. The results of included 
studies were tabulated for the following outcomes: weighted 
mean difference (WMD) or standardized mean difference 
(SMD) from MADRS or Ham-D scores, response rate, remis-
sion rate, and withdrawal rate owing to adverse events (if not 
available, then all-cause withdrawal rate was used). Unless 
otherwise indicated, response is defined as a 50% or greater 
reduction in scale scores from baseline, while remission is 
defined as either MADRS # 12 or Ham-D # 7, depending 
on the scale used.
Results
The initial electronic search yielded 98 articles, of which 
24 met the inclusion criteria as a pooled analysis or 
  meta-analysis study (see Figure 1). Sixteen pooled analysis 
studies and six meta-analysis studies were identified. Two 
additional meta-analysis studies were “hybrid” studies, but 
were classified as pooled studies because they primarily Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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reported pooled analyses of individual patient data, with only 
limited analyses of summary data.16,17
Of the 18 pooled analysis studies, we excluded five 
studies18–22 primarily focusing on topics (symptom clusters, 
onset of action, predictors of response) other than efficacy, 
two studies17,23 which were considered  subsets of subsequent 
larger pooled studies, and five studies24–28 focusing on sever-
ity analyses only. This left six pooled analysis studies for 
review (Table 1). Several of the pooled studies also analyzed 
  outcomes for a severely depressed patient subgroup, defined 
as baseline MADRS $ 30 (Table 2). All studies except one29 
used data from randomized controlled trials sponsored by 
the manufacturer or distributor of escitalopram (Lundbeck 
or Forest).
Of the six meta-analysis (and two hybrid) studies, two 
studies17,30 were excluded because subsequent studies were 
considered updates, but one16 of the hybrid studies included 
a direct meta-analysis, hence six meta-analysis studies were 
eligible for review (Table 3).
An important consideration for systematic reviews and 
meta-analyses is the “universe” of randomized controlled 
  trials from which trials are selected. Inspection of the 
included trials from these meta-analysis studies revealed 
a total of 22 comparative randomized controlled trials 
of   escitalopram with citalopram (eight trials), fluoxetine 
(three trials), paroxetine (two trials), sertraline (two trials), 
  bupropion XL (two trials), duloxetine (three trials), and 
venlafaxine XR (two trials). An updated electronic search 
of PubMed through to November 2010 found one additional 
trial with   desvenlafaxine in postmenopausal women.31
Pooled analysis studies
Two pooled analysis studies examined escitalopram 
  compared with other SSRIs. Kennedy et al16 pooled five   trials 
with citalopram and found superiority for escitalopram in 
mean MADRS difference (1.2 points, P = 0.00094) and 
response rate difference (7.4%, P = 0.0043), but remission 
rate   difference missed significance (5.1%, P = 0.0517). 
In addition, Kennedy et al also reported superiority for 
escitalopram over combined SSRIs (12 trials of   citalopram, 
fluoxetine, paroxetine, sertraline), although this was 
largely explained by differences between escitalopram and 
  citalopram. There was no difference in withdrawal rate owing 
to adverse events between escitalopram and SSRIs. Another 
study pooled data from two trials with paroxetine and found 
superiority for escitalopram in mean MADRS difference 
(2 points, P , 0.01), response difference (6.2%, P , 0.05), 
remission difference (6.4%, P , 0.05) and withdrawal rate 
difference (5.1%, P , 0.01).32
Three pooled studies examined escitalopram compared 
with SNRIs. In the first, data from two randomized controlled 
trials with venlafaxine XR were pooled.33 No significant 
differences were found in MADRS difference, response, or 
remission rates. However, the withdrawal rate for adverse 
events was lower for escitalopram (7.5% versus 11.2%, 
P , 0.05). The second study pooled data from two trials 
with duloxetine.34 Escitalopram was superior in MADRS 
  difference (2.6 points, P , 0.01), response difference (13.9%, 
P , 0.001) and remission difference (9.9%, P , 0.05). The 
withdrawal rate for adverse events also favored escitalo-
pram (12.9% versus 24.3%, P , 0.001). The third study 
pooled results from the four randomized controlled trials of 
duloxetine and venlafaxine XR included in the previously 
described studies.35 (Note that Kennedy et al16 also reported a 
pooled analysis of these same four SNRI trials, but the results 
were identical.) At week 8, escitalopram was superior to the 
two SNRIs in MADRS difference (1.7 points, P , 0.01), 
and response and remission differences (9.3%, P , 0.01, 
and 7.2%, P , 0.05, respectively). The withdrawal rate for 
adverse events was also lower for escitalopram than the 
SNRIs (5.3% versus 12.0%, P , 0.0001).
A comprehensive pooled analysis compared 16 ran-
domized controlled trials of escitalopram and six com-
parator antidepressants (citalopram, fluoxetine, paroxetine, 
Studies identified 
through initial search
(N = 98)
Studies meeting 
initial criteria
(N = 24)
Studies included 
in review
(N = 12)
Excluded, N = 64
• Not meta-analysis or
Excluded, N = 12
• Focus other than efficacy
• Subsequent studies
considered updates
or subgroup analysis only
pooled analysis
Figure 1 Flow diagram for identification of pooled and meta-analysis studies of 
comparative efficacy of escitalopram.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Efficacy of escitalopram for MDD
  sertraline, duloxetine, venlafaxine), which included all the 
trials in the previously described pooled studies.16 Trials 
less than 8 weeks (two trials) and trials that did not include 
the MADRS (four trials) were excluded from this analysis. 
At week 8,   escitalopram was superior to all comparators, with 
an estimated MADRS difference of 1.1 points (P , 0.0001), 
response difference of 5.4% (P , 0.0001), remission differ-
ence of 3.7% (P , 0.006), and withdrawal rate difference of 
2.5% (P , 0.0007).
One final pooled analysis29 involved two randomized 
  controlled trials with bupropion XL, both sponsored by the 
manufacturer of bupropion (GlaxoSmithKline). No   significant 
differences were found between escitalopram and bupropion 
XL in the efficacy outcomes or withdrawal rates.
Several of the pooled analysis studies also examined 
outcomes for a subgroup of patients who were severely 
depressed at baseline (Table 2). In these studies, when 
  compared with the total group, the severely depressed 
  subgroup showed increased differences between escitalo-
pram and the comparator. In the Kennedy et al16 pooled 
analysis of five citalopram trials, the MADRS difference 
at week 8 in patients with baseline MADRS $ 30 favored 
escitalopram by 2.0 points (P = 0.0013), as did the response 
rate difference (11.3%, P = 0.0012), although the remission 
rate difference of 6.3% was not statistically significant. 
Similarly, Kornstein et al35 also found that the differences 
between escitalopram and SNRIs in the severely ill subgroup 
were greater than those overall, with a significant MADRS 
difference of 2.9 points and response/remission differences 
of 14.4%/13.4% (P , 0.001). Finally, the Kennedy et al16 
comprehensive pooled analysis of 16 trials found that the 
MADRS difference between escitalopram and all compara-
tors in the severely depressed subgroup was 1.8 points, with 
a response difference of 8.6% and a remission difference of 
6.1%, all of which were statistically significant.
Meta-analysis studies
A Cochrane systematic review of escitalopram was   conducted 
as one of a series systematically evaluating the newer genera-
tion antidepressants. Cipriani et al36 compared the efficacy and 
acceptability of escitalopram with other antidepressants in 20 
published and unpublished trials, searched through to July 
2008. In acute-phase treatment (6–12 weeks), escitalopram 
was shown to be significantly superior to   citalopram (based 
on six trials) in SMD at endpoint (-0.17, P , 0.009) and in 
achieving response (60.7% versus 53.8%, P , 0.006) and 
remission (47.7% versus 38.5%, P , 0.02), and superior to 
fluoxetine (based on three trials) in SMD (-0.17, P , 0.02). 
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There were no other significant differences in efficacy 
between escitalopram and paroxetine, sertraline, bupropion, 
duloxetine, and venlafaxine, but these analyses were limited 
to 2–3 trials per comparison.
Three other meta-analyses specifically focused on 
  comparison of escitalopram versus citalopram. Although the 
included studies were similar for all three, each study used 
different analyses and reached different clinical conclusions. 
Gartlehner et al37 included five randomized controlled trials, of 
which one was unpublished, all using the MADRS as primary 
outcome. At week 8, escitalopram was superior in WMD 
(1.13 MADRS points, P = 0.02) and response rate difference 
(about 7%, P , 0.05). Trkulja38 included seven randomized 
controlled trials (including all those in Gartlehner et al37), but 
outcomes were analyzed for each weekly time point sepa-
rately, and only those trials that reported data for that time 
point were included. At the week 8 time point, based on five 
trials, escitalopram was significantly superior, with a WMD of 
1.23 (P = 0.012) and a response difference of 7% (P = 0.007). 
The week 6 time point results, based on four trials, showed a 
WMD of 1.73 (P = 0.004). Despite the statistically significant 
findings, the authors of these two studies concluded that the 
differences were not clinically relevant.
In contrast, Montgomery et al39 meta-analyzed eight ran-
domized controlled citalopram trials, including all those in the 
Trkulja38 review plus an additional small (n = 56) randomized 
controlled trial reported in a Chinese language journal. The 
outcomes included WMD (based on the six trials using the 
MADRS), response rates (based on all eight   trials), and remis-
sion rates (based on the MADRS, reported in only four trials). 
The primary results showed superiority for escitalopram, with 
a WMD of 1.7 (P = 0.0002), a response difference of 8.3%, 
and a remission difference of 17.6%. These differences were 
regarded by the study authors as clinically significant.
Finally, Kennedy et al16 included a limited meta-analysis 
of the five randomized controlled trials with the SNRIs, 
duloxetine and venlafaxine XR. In contrast with the pooled 
analysis results, this was conducted using Ham-D scores 
and mixed model repeated measures analyses of the primary 
trials. With these parameters, there were no significant 
  differences in the Ham-D WMD between escitalopram and 
duloxetine (three trials) or between escitalopram and the 
combined SNRIs (five trials).
Multiple treatments meta-analysis 
studies
Two of the escitalopram meta-analyses used a newer sta-
tistical approach, multiple-treatments meta-analysis, also 
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called   network meta-analysis, to compare the efficacy and 
  acceptability of 12 new-generation antidepressants. In 
  contrast with a usual meta-analysis, where direct comparisons 
of two agents are analyzed, a multiple-treatments meta-
analysis allows for the integration of data from both direct 
comparisons (when two agents are compared within one 
randomized controlled trial) and indirect comparisons (when 
two agents are compared by combining results based on ran-
domized controlled trials with a common third agent).40,41
Gartlehner et al37 included 114 randomized controlled 
trials (with 12 comparative escitalopram trials) searched 
through to April 2007, including unpublished trials. 
The primary efficacy outcomes were WMD and response 
rate. Direct comparison using meta-analysis was conducted 
if there were three or more trials, otherwise indirect compari-
sons of response rates were conducted using metaregression 
and modified network analysis. Only the direct meta-analyses 
found significant results in response rates: escitalopram supe-
rior to citalopram (described in the previous meta-analysis 
section), sertraline superior to fluoxetine, and venlafaxine 
superior to fluoxetine. However, the study authors questioned 
the clinical relevance of the small differences found.
Cipriani et al42 conducted a multiple treatments 
  meta-analysis that included 117 randomized controlled trials 
(with 19 escitalopram trials) from 1991 to November 2007, 
including 15 unpublished trials obtained from pharmaceuti-
cal company websites. The primary outcomes were efficacy, 
defined as the response rate, and acceptability, defined as the 
proportion of patients who withdrew from the study for all 
causes. Compared with the other antidepressants, the main 
efficacy results found superiority in response rates for escit-
alopram, mirtazapine, sertraline, and venlafaxine; inferiority 
was found only for reboxetine. A series of sensitivity analyses 
(examining dosing, imputation strategy, sponsorship, etc) 
did not change the results. Four antidepressants were also 
found to be superior in acceptability, ie, bupropion, citalo-
pram, escitalopram, and sertraline. The authors concluded 
that these were clinically relevant differences in efficacy 
and acceptability.
Discussion
This systematic review identified a number of studies using 
pooled analyses of individual patient data and meta-analyses 
of summary trial data evaluating the comparative efficacy of 
escitalopram, but differences in criteria for inclusion of trials 
and statistical methodologies of these studies make direct 
comparisons difficult. In addition, the “universe” of known 
trials available for meta-analysis is a moving target, as new 
randomized controlled trials are added to the clinical trials 
database. For example, there were 22 comparative random-
ized controlled trials of escitalopram available for review, but 
none of the meta-analysis studies included all of them.
Overall, a comprehensive pooled analysis16 and a   network 
meta-analysis42 both found evidence for superiority of esci-
talopram over other comparators, although one modified 
network meta-analysis37 did not. However, there is consistent 
evidence that escitalopram is superior in efficacy to other 
SSRIs, especially citalopram. The pooled and meta-analysis 
studies with citalopram (with 3–8 trials included in each 
study) show consistent statistically significant findings in 
favor of escitalopram in WMD (1.13–1.73 MADRS points), 
response rate difference (7.0%–8.3%), and   remission rate dif-
ference (5.1%–17.6%). A pooled analysis of two   paroxetine 
trials also found superiority of escitalopram in these out-
comes. Similarly, a pooled comparison of escitalopram with 
all SSRIs combined together (12 trials) also found significant 
differences in favor of escitalopram, although the effect sizes 
were smaller.16
The comparative efficacy of escitalopram with SNRIs and 
other agents is less clear. Pooled analyses found   significant 
superiority over duloxetine,34 but no differences with 
  venlafaxine XR,33 while meta-analyses found no differences 
with either.36,37 A pooled analysis35 (using MADRS scores) of 
the two SNRIs combined also favored escitalopram, while a 
meta-analysis16 (using Ham-D scores) did not. The reason for 
the discrepancy between the pooled and meta-analysis studies 
of SNRIs may be owing to the small number of randomized 
controlled trials available, in that pooled analysis of individ-
ual patient data has greater power to detect differences than 
meta-analysis. The one comparison with bupropion (a pooled 
analysis of two trials) found no comparative differences, but 
in that analysis the bupropion group did not significantly 
differentiate from placebo in the primary outcome (WMD), 
whereas the escitalopram group did.29
Despite the consistent evidence for superiority of escitalo-
pram over SSRIs, there is still contention about the clinical 
importance of the differences. For example, very similar 
results were found in the pooled and meta-analysis studies 
with citalopram, but some authors interpreted their results as 
clinically relevant, while others did not. A major issue is that 
there is still no consensus about the definition for a minimal 
clinically important difference (MCID) for drug-placebo 
comparisons. Some suggested criteria for drug-placebo 
MCID with antidepressants include a MADRS difference of 
2 points or a response rate difference of 10% (corresponding 
to a number needed to treat of 10).43 Moreover, it is unclear Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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whether active drug comparisons should use the same MCID 
as drug-placebo comparisons. If so, to be considered superior, 
an antidepressant would need to show an additional 2-point 
MADRS difference against a comparator, or 4 points relative 
to placebo; this seems to be an unreasonably difficult thresh-
old to achieve. Hence, some investigators have suggested that 
the MCID between two active agents should be half the drug-
placebo MCID, corresponding to at least 1 point MADRS 
difference, or 5% response rate difference (number needed 
to treat = 20).44 Using these MCID criteria, the superiority 
of escitalopram over citalopram and other SSRIs would be 
considered clinically relevant.
Because of the high placebo response in clinical trials, 
some investigators have also suggested using methods to 
increase assay sensitivity for detecting clinically relevant 
differences between antidepressants. One such method is to 
examine subgroups of patients with higher baseline severity 
of symptoms. The more severely depressed subgroup, usually 
defined as MADRS $ 30 or Ham-D $ 25, may have better 
responses to medication and/or lower responses to placebo, 
either of which make it easier to detect specific effects of 
the active medications. In this review, the pooled analysis 
studies that examined severely depressed subgroups found 
larger efficacy differences for escitalopram, with WMDs 
ranging from 1.4 to 3.8 MADRS points and response rate 
differences ranging from 6.6% to 19.1%. These differences 
are well within any definition for clinical importance. The 
results are consistent with evidence from pooled analyses 
that the comparative effect sizes in favor of escitalopram 
increase with increasing baseline severity.16,24,25 They are 
also consistent with those from head-to-head randomized 
controlled trials that prospectively enrolled patients with 
severe depression.45,46 Together, these studies provide some 
validation that the modest efficacy differences with escitalo-
pram are clinically significant.
An important question is why should escitalopram have 
superior efficacy compared with racemic citalopram and 
other SSRIs? Biochemical studies have demonstrated that 
there are two distinct binding sites on the serotonin trans-
porter protein, ie, a high-affinity, primary binding site that 
mediates the inhibition of serotonin reuptake, and a low affin-
ity site that allosterically modulates the affinity of ligands at 
the primary site.9,47 Escitalopram uniquely binds to both the 
primary and allosteric sites,48 leading to enhanced serotoner-
gic neurotransmission and subsequent downstream effects on 
synaptic plasticity and neurogenesis.49–51 The R-enantiomer 
in racemic citalopram binds only to the allosteric site, which 
interferes with the effects of escitalopram and counteracts 
its allosteric modulatory action.9,52 The additional allosteric 
mechanism of escitalopram, which appears to be unique 
among SSRI antidepressants,53 may explain its efficacy 
advantages in patients with MDD.
This systematic review also found evidence from the pooled 
analysis studies that escitalopram had lower withdrawal rates 
owing to adverse events compared with SNRIs, but not with 
citalopram or other SSRIs. Similarly, a multiple treatments 
meta-analysis found that escitalopram was one of four newer-
generation antidepressants (along with bupropion, citalopram, 
and sertraline) that showed superior acceptability (based on 
all-cause withdrawals).42 These results are also consistent 
with a pooled analysis from a clinical trial database of over 
4000 patients showing that escitalopram demonstrated very 
good safety and tolerability for treatment of MDD and anxiety 
disorders.13 Like other SSRIs, escitalopram is associated with 
sexual side effects, with pooled studies showing higher rates 
compared with bupropion.29 However, a meta-analysis of stud-
ies using specific sexual functioning questionnaires suggested 
that escitalopram may have lower rates than other SSRIs.54
The limitations of this systematic review must be 
  considered. The meta-analysis and pooled studies were 
based on randomized controlled trials which mostly were 
eight weeks or less in duration. It is possible that any efficacy 
differences between escitalopram and comparators decrease 
over time. Similarly, doses may not have been optimized in 
the trials and results of randomized controlled trials may not 
be generalizable to more real-world conditions. Combining 
agents within a class (eg, all SSRIs, all SNRIs) as compara-
tors may not be valid, especially because there is evidence 
that some agents within a class have greater efficacy than 
others. Finally, the total number of comparative randomized 
controlled trials of escitalopram (23 trials to November 2010) 
in MDD is still relatively low.
Conclusion
This systematic review of pooled analysis and meta-  analysis 
studies found that escitalopram has superior efficacy 
  compared with citalopram and SSRIs combined, and that 
the efficacy differences are modest but clinically relevant, 
especially in more severely depressed patients. Escitalopram 
also has at least similar efficacy to SNRIs and bupropion. In 
multiple-treatments (network) meta-analysis studies, escit-
alopram was one of four newer-generation antidepressants 
with evidence for superiority compared with the others. The 
efficacy differences of escitalopram may be related to its dual 
mechanism of action on the primary and allosteric binding 
sites on the serotonin transporter.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Many clinical factors, including efficacy, side effect 
profile, drug interactions, relapse prevention, simplicity of 
use, and cost-effectiveness must be considered together when 
making a clinical decision for a first-choice antidepressant.7 
This systematic review of the efficacy of escitalopram should 
add to the evidence database to help guide clinicians on the 
choice of an appropriate medication.
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